Gossamer Bio, Inc. - Common Stock (GOSS)
Frequently Asked Questions About Gossamer Bio, Inc. - Common Stock (GOSS)
How can I contact Gossamer Bio for investor inquiries?
For investor inquiries, Gossamer Bio provides contact information on its investor relations page. Interested parties can reach out via email or phone to obtain information about the company, its performance, and its pipeline.
How can I invest in Gossamer Bio?
To invest in Gossamer Bio, you can purchase shares through a brokerage account that offers access to public stock exchanges. You should consider your investment strategy and perform due diligence before buying shares.
How does Gossamer Bio approach patient engagement?
Gossamer Bio places a high value on patient engagement by actively involving patients in its clinical trials and seeking their feedback. The company believes that understanding the patient perspective is critical for developing effective therapies.
How does Gossamer Bio ensure compliance with regulations?
Gossamer Bio adheres to strict regulatory guidelines and standards set by health authorities such as the FDA and EMA. The company maintains a compliance program that includes regular audits, employee training, and engagement with regulatory agencies.
Is Gossamer Bio publicly traded?
Yes, Gossamer Bio is publicly traded on the Nasdaq stock exchange under the ticker symbol GOSS. The company went public in 2018, which allowed it to raise capital to support its ongoing research and development activities.
What are Gossamer Bio's core values?
Gossamer Bio's core values include a commitment to science and innovation, integrity in its business practices, and a focus on patient-centered solutions. These values guide the company's operations and decision-making processes.
What are the future plans for Gossamer Bio?
Gossamer Bio plans to continue advancing its pipeline of product candidates through clinical development and to explore new therapeutic areas. The company aims to expand its collaborations and partnerships to enhance its drug development efforts.
What are the key product candidates in Gossamer Bio's pipeline?
Gossamer Bio's pipeline includes several promising candidates, such as GB001, which is being developed for the treatment of asthma and other allergic conditions, and GB002, which is focused on immunology indications. Detailed information about their pipeline can typically be found on the company's investor relations page.
What challenges is Gossamer Bio currently facing?
Like many biotech companies, Gossamer Bio faces challenges such as competition in the biopharmaceutical market, regulatory hurdles for drug approval, and the need to secure funding for ongoing research and development.
What does Gossamer Bio, Inc. do?
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative medicines for patients with significant unmet medical needs. The company aims to leverage its unique expertise in drug development to create targeted therapies that can address various diseases.
What is Gossamer Bio's business model?
Gossamer Bio's business model combines drug discovery and development with strategic partnerships and collaborations. The company seeks to develop proprietary drug candidates and may also consider partnerships to bring products to market.
What is Gossamer Bio's mission?
Gossamer Bio's mission is to advance innovative medicines that make a meaningful difference in the lives of patients with serious conditions. The company is dedicated to addressing unmet medical needs through clinical research and development.
What is the primary focus of Gossamer Bio's research?
Gossamer Bio's primary focus is on developing therapies for immunology, oncology, and rare diseases. The company aims to create innovative solutions that can significantly improve patient outcomes in these challenging areas.
What milestones has Gossamer Bio achieved?
Gossamer Bio has achieved several milestones since its founding, including successful clinical study results for its product candidates and strategic partnerships that enhance its research capabilities. Specific milestones can be found in press releases and annual reports.
What partnerships does Gossamer Bio have?
Gossamer Bio has established partnerships and collaborations with various pharmaceutical companies and academic institutions to enhance its research capabilities and accelerate its drug development efforts. Specific partnerships may vary and can be found in investor presentations.
When does Gossamer Bio report its earnings?
Gossamer Bio typically reports its earnings quarterly, providing updates on its financial performance, pipeline progress, and other strategic developments. The specific dates can be found on the company’s investor relations website.
When was Gossamer Bio founded?
Gossamer Bio was founded in 2015. Since its inception, the company has focused on advancing its pipeline of product candidates aimed at treating various diseases with high unmet medical needs.
Where is Gossamer Bio located?
Gossamer Bio is headquartered in San Diego, California. The location positions the company within a vibrant life sciences ecosystem, allowing it to collaborate with other biotech firms, research institutions, and industry leaders.
Who are the key executives at Gossamer Bio?
The executive team at Gossamer Bio includes talented individuals with extensive experience in the life sciences sector. Notable executives often include the CEO, CFO, and CMO, who guide the company's strategic direction and operational execution.
What is the current price of Gossamer Bio, Inc. - Common Stock?
The current price of Gossamer Bio, Inc. - Common Stock is 0.8302
When was Gossamer Bio, Inc. - Common Stock last traded?
The last trade of Gossamer Bio, Inc. - Common Stock was at 2:53 pm EDT on April 4th, 2025
What is the market capitalization of Gossamer Bio, Inc. - Common Stock?
The market capitalization of Gossamer Bio, Inc. - Common Stock is 63.09M
How many shares of Gossamer Bio, Inc. - Common Stock are outstanding?
Gossamer Bio, Inc. - Common Stock has 75.99M shares outstanding.